Glucose-dependent insulinotropic polypeptide

Biomarker

1 paper

Human trial1

Latest

51 in 12 months

The Journal of Clinical Endocrinology and Metabolism47 min

Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis

ReviewInterventions

Paper

LUMEN ET VIRTUS10 Oct

Tirzepatide, body composition and risk of sarcopenia: a critical narrative review

ReviewTirzepatide

Paper

Cell Metabolism8 Oct

A triple-target drug cut body weight by up to 19.7% in a trial

Average body weight fell between 13.6% and 19.7% across drug doses compared with 2.0% on placebo over 24 weeks.Average body weight fell between 13.6% and 19.7% across drug doses compared with 2.0% on placebo over 24 weeks.

Randomised trial in 205 peopleInterventions

Paper

Pharmacology Research & Perspectives5 Oct

Glucagon-Like Peptide-1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications

ReviewGLP-1 receptor agonists

Paper

Clinics in Dermatology2 Oct

GLP-1 receptor agonists in psoriasis management

ReviewGLP-1 receptor agonists

Paper

Obesity Pillars2 Oct

Fat and lean mass changes during incretin-based therapy with structured exercise and nutritional support: A retrospective real-world pilot study

Cohort study of 11 peopleExercise

Paper

Frontiers in Cardiovascular Medicine2 Oct

Cardiovascular protection beyond glucose lowering: GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonism in contemporary cardiology

ReviewGLP-1 receptor agonists

Paper

Endocrine Journal1 Oct

Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study-East Shizuoka Tirzepatide (ESTATE) study

Cohort study of 88 peopleTirzepatide

Paper

The New England Journal of Medicine1 Oct

Retatrutide reduces weight and pain in adults with obesity

Mean body weight fell up to 25.0% with retatrutide versus 3.9% on placebo over 80 weeks in adults with obesity.Mean body weight fell up to 25.0% with retatrutide versus 3.9% on placebo over 80 weeks in adults with obesity.

Randomised trial in 2,339 peopleRetatrutide

Paper

Journal of Managed Care & Specialty Pharmacy30 Sep

Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes

Cohort study of 10,702 peopleTirzepatide

Paper

Glucose-dependent insulinotropic polypeptide

Latest

Related